Asset
Zeleciment rostudirsen
Dyne Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05524883 | phase1_2 | active_not_recruiting | 2022-08-12 | 2031-09-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
FDA applications (0)
This company has no applications containing this asset.